{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_216", "batch_size": 200, "batch_pos": 75, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment describes technology advantages, not the virus impact using vivid language.", "method": "llm_batch", "batch_id": "batch_2_18820", "batch_size": 200, "batch_pos": 68, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"hop_idx": 3, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_3_14860", "batch_size": 200, "batch_pos": 42, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment describes advantages of technology, not the impact of the virus using a moderate verb and scale.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_3_14860_r1", "batch_size": 200, "batch_pos": 42, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_2216", "batch_size": 200, "batch_pos": 29, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment lists advantages of mRNA technology, lacking explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_6812", "batch_size": 200, "batch_pos": 28, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_17896", "batch_size": 200, "batch_pos": 13, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation about risk or impact.", "method": "llm_batch", "batch_id": "batch_7_17716", "batch_size": 200, "batch_pos": 9, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Quotes benefits/capabilities of technology ('offers advantages in efficacy, speed... scalability, and reliability') without explicit active reassurance (Guard 2).", "method": "llm_batch", "batch_id": "batch_8_14236", "batch_size": 200, "batch_pos": 169, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
